Compositions and methods for treating obesity and diabetes
Inventors
Burow, Matthew E. • Boue, Stephen M. • Wang, Thomas T. Y. • Bhatnagar, Deepak • Wood, Charles E. • Helman, Mark L.
Assignees
Tulane University • US Department of Agriculture USDA • Wake Forest University Health Sciences • Microbiome Therapeutics LLC
Publication Number
US-8987198-B2
Publication Date
2015-03-24
Expiration Date
2030-12-22
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.
Core Innovation
The invention relates to the use of isoflavonoid phytoalexin compounds, specifically Glyceollins I, II, and III, isolated from soy plants grown under stressed conditions, as a method of treating and preventing conditions such as hyperlipidemia, obesity, excessive cholesterol, cardiovascular diseases, diabetes, liver disease, and related metabolic disorders. The glyceollins modulate expression of genes involved in lipid and carbohydrate metabolism, adipocytokine signaling, PPAR signaling, and Liver X Receptor (LXR) pathways, providing a novel therapeutic approach to metabolic diseases.
The problem addressed is the rising epidemic of obesity and its associated metabolic disorders such as type 2 diabetes and cardiovascular disease, which are linked to lipid and carbohydrate metabolism abnormalities and inflammation. Current interventions are inadequate, and the inventors recognized the potential of soy phytoalexins, particularly glyceollins, to modulate key metabolic pathways distinct from standard soy isoflavones such as genistein and daidzein, thus providing a new avenue for prevention and treatment of these conditions.
The invention provides methods of modulating gene expression linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, and extracellular matrix receptor interaction by administering compositions comprising isolated glyceollins to animals in need thereof. These glyceollins can be isolated from elicited soy, administered in specified concentration ranges, and result in altered expression of specific genes that contribute to improved metabolic profiles and stimulation of glucose uptake, thereby addressing obesity, diabetes, and related disorders.
Claims Coverage
The patent contains two independent claims directed to methods for treating metabolic disorders and stimulating glucose uptake using isolated glyceollins.
Method of treating metabolic disorders with glyceollins
Administering a composition comprising at least one isolated glyceollin to an animal in need, wherein the glyceollin concentration in the composition is about 100 nM to about 50 μM, to treat hyperlipidemia, obesity, excessive cholesterol, diabetes, or combinations thereof.
Method of stimulating glucose uptake with glyceollins
Administering a composition comprising at least one isolated glyceollin to an animal in need in a concentration of about 100 nM to about 50 μM, optionally with insulin or coadministered with insulin, to stimulate glucose uptake.
The independent claims focus on administering isolated glyceollins in defined concentrations, isolated from elicited soy, to treat metabolic diseases and stimulate glucose uptake, including compositions optionally combined with insulin.
Stated Advantages
Glyceollins modulate multiple metabolic pathways including adipocytokine signaling, lipid and carbohydrate metabolism, PPAR and insulin signaling.
Glyceollin-enriched soy protein displays distinct gene expression profiles compared to standard soy, suggesting unique metabolic benefits.
Administration of glyceollins lowers serum total cholesterol, specifically non-high-density lipoprotein cholesterol.
Glyceollins stimulate glucose uptake in adipocytes independently of insulin, indicating potential for improved glucose metabolism.
Documented Applications
Treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof in animals, including humans.
Stimulating glucose uptake in animals needing improved glucose metabolism, for example to treat diabetes or insulin resistance.
Use in dietary compositions containing glyceollins for prevention or minimization of obesity, dyslipidemia, atherosclerosis, or diabetes.
Interested in licensing this patent?